Aptose Biosciences Inc. Files 8-K

Ticker: APTOF · Form: 8-K · Filed: Apr 1, 2025 · CIK: 882361

Sentiment: neutral

Topics: sec-filing, corporate-update, biotech

Related Tickers: APTO

TL;DR

APTO filed an 8-K, confirming their business is in biological products. Nothing major, just a routine update.

AI Summary

On April 1, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing indicates the company's primary business is in Biological Products, specifically excluding diagnostic substances. Aptose Biosciences Inc. is incorporated in Canada and has its principal executive offices in Toronto.

Why It Matters

This 8-K filing provides an update on Aptose Biosciences Inc.'s corporate status and business classification with the SEC, which is important for investors tracking the company's regulatory filings.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any new material information that would significantly alter the company's risk profile.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Aptose Biosciences Inc. as indicated in this filing?

The filing indicates Aptose Biosciences Inc.'s Standard Industrial Classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is April 1, 2025.

Where is Aptose Biosciences Inc. incorporated?

Aptose Biosciences Inc. is incorporated in Canada.

What is the SEC file number for Aptose Biosciences Inc.?

The SEC file number for Aptose Biosciences Inc. is 001-32001.

What is the business address of Aptose Biosciences Inc.?

The business address is 66 WELLINGTON STREET WEST, SUITE 5300, TD BANK TOWER BOX 48, TORONTO, A6, M5K 1E6.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Aptose Biosciences Inc. (APTOF).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing